I’m sure the company will make the right decision based on the facts. If an offer is made that on balance is in the best interests of shareholders I’m sure they will take it.
If Efti continues to show significant clinical benefit then getting Efti into patients in the shortest time span is also an important consideration. I’m not sure Immutep going it alone would be the fastest route.
Media, page-192
-
- There are more pages in this discussion • 552 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
-0.010(3.13%) |
Mkt cap ! $450.9M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 32.8¢ | 31.0¢ | $758.7K | 2.412M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 166349 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.5¢ | 312504 | 6 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |